共 50 条
Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis
被引:6
|作者:
Wandji, Line Carolle Ntandja
[1
]
Ningarhari, Massih
[1
]
Lassailly, Guillaume
[1
]
Dharancy, Sebastien
[1
]
Boleslawski, Emmanuel
[2
]
Mathurin, Philippe
[1
]
Louvet, Alexandre
[1
,3
]
机构:
[1] Univ Lille, Inserm, U1286 INFINITE Inst Translat Res Inflammat, CHU Lille, F-59000 Lille, France
[2] Univ Lille, Inserm, U1189 ONCO THAI Image Assisted Laser Therapy Oncol, CHU Lille, F-59000 Lille, France
[3] Hop Huriez, Serv Malad Appareil Digest, Rue Polonowski, F-59037 Lille, France
关键词:
alcohol;
alcohol-related liver disease;
alcohol-related hepatitis;
liver transplantation;
survival;
LONG-TERM SURVIVAL;
FOLLOW-UP;
CLINICAL GUIDELINE;
SCREENING TOOL;
RELAPSE;
CIRRHOSIS;
RISK;
RECOMMENDATIONS;
CONSUMPTION;
PREDNISOLONE;
D O I:
10.1016/j.jceh.2022.06.013
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Alcohol-related liver disease (ARLD) remains one of the leading causes of chronic liver disease and the prevalence of alcohol-related cirrhosis is still increasing worldwide. Thus, ARLD is one of the leading indications for liver transplantation (LT) worldwide especially after the arrival of direct-acting antivirals for chronic hepatitis C infec-tion. Despite the risk of alcohol relapse, the outcomes of LT for ARLD are as good as for other indications such as hepatocellular carcinoma (HCC), with 1-, 5-, and 10-year survival rates of 85%, 74%, and 59%, respectively. Despite these good results, certain questions concerning LT for ARLD remain unanswered, in particular because of persistent organ shortages. As a result, too many transplantation centers continue to require 6 months of absti-nence from alcohol for patients with ARLD before LT to reduce the risk of alcohol relapse even though compel-ling data show the poor prognostic value of this criterion. A recent pilot study even observed a lower alcohol relapse rate in patients receiving LT after less than 6 months of abstinence as long as addictological follow-up is reinforced. Thus, the question should not be whether LT should be offered to patients with ARLD but how to select patients who will benefit from this treatment. ( J CLIN EXP HEPATOL 2023;13:127-138)
引用
收藏
页码:127 / 138
页数:12
相关论文